Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantag

Neoadjuvant nivolumab plus chemotherapy produced a long-term event-free survival benefit vs chemotherapy alone in patients with resectable non–small cell lung cancer, independent of whether patients underwent minimally invasive surgery or thoracotomy or complete or partial resection of the lung.

Related Keywords

Denmark , Copenhagen , Køavn , France , Paris , France General , Saclay , Nicolas Girard , Leo Pharma , Girardn Neoadjuvant , Daiichi Sankyo , Paris Saclay University , Thorax Institute Curie Montsouris , Pfizer , Boehringer Ingelheim , Medtronic , Bristol Myers Squibb , Astrazeneca , Drug Administration , Novartis , European Lung Cancer Congress , Amgen , Lung Cancer Congress , Hoffman La Roche , Merck Sharp , Bristol Myers , Myers Squibb , Nivolumab , Neoadjuvant , Non Small Cell Lung Cancer , Felcc , Nsclc , Nct02998528 , Checkmate 816 Trial ,